Keros CEO Seehra becomes Chair; Rovaldi promoted to President effective July 1

Keros Therapeutics, Inc.

CEO Jasbir Seehra appointed Chair of Board, effective July 1, 2024, succeeding Carl Gordon who remains director.
Christopher Rovaldi promoted to President in addition to COO, effective July 1, 2024, replacing Seehra as President.
Jean-Jacques Bienaimé appointed Lead Independent Director, effective July 1, with a new $25,000 annual retainer.
Leadership changes come as Keros prepares for first registrational Phase 3 trial of elritercept (KER-050).

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carl L. Gordon

Chair of the Board

KROS · Keros Therapeutics, Inc.

Effective: 2024-06-30
Successor: Jasbir Seehra
Filed: June 17, 2024, 7:59 PM ET

Carl L. Gordon currently serves as the Chair of the Board and, effective June 30, 2024, will resign from such position and serve as a member of the Board.

Appointed

Jean-Jacques Bienaimé

Lead Independent Director

KROS · Keros Therapeutics, Inc.

Effective: 2024-07-01
Filed: June 17, 2024, 7:59 PM ET

the Board appointed Jean-Jacques Bienaimé as Lead Independent Director, effective July 1, 2024.

Role change

Christopher Rovaldi

President and Chief Operating Officer

KROS · Keros Therapeutics, Inc.

Effective: 2024-07-01
Filed: June 17, 2024, 7:59 PM ET

The Board appointed Christopher Rovaldi to the additional position as the Company’s President, effective July 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carl L. Gordon resigned as Chair of the Board at Keros Therapeutics, Inc..

Action: resigned
Role: Chair of the Board

Exact text from the filing

Carl L. Gordon currently serves as the Chair of the Board and, effective June 30, 2024, will resign from such position and serve as a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jean-Jacques Bienaimé was appointed as Lead Independent Director at Keros Therapeutics, Inc..

Action: appointed
Role: Lead Independent Director

Exact text from the filing

the Board appointed Jean-Jacques Bienaimé as Lead Independent Director, effective July 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Rovaldi was appointed as President and Chief Operating Officer at Keros Therapeutics, Inc..

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

The Board appointed Christopher Rovaldi to the additional position as the Company’s President, effective July 1, 2024.

View on SEC.gov

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-24-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.